Finance entity

Candel Therapeutics

Company CADL

markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Copart, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window.

Last mentioned: Feb 20, 2026

Entity pulse

Recent coverage · Candel Therapeutics

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Candel Therapeutics

markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Copart, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. Candel Therapeutics appears in 1 tracked Finance story from February 20, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 75 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Candel Therapeutics. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Candel Public Offering

    Candel Therapeutics prices $100M public offering at $5.45 per share.

  2. Trial Data Release

    Grail shares slide as NHS-Galleri trial misses primary endpoint for late-stage cancer reduction.

  3. GDP Release

    U.S. government scheduled to release Q4 GDP growth figures at 8:30 AM ET.

  4. Grail Earnings

    Grail reports Q4 and Full Year 2025 financial results, beating revenue and EPS estimates.

Stories mentioning Candel Therapeutics 1

Candel Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.